Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBT 986 BS in Subjects With Renal Impairment
NCT02254070Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2003
- Primary completion
- Aug 2004
01
Overview
Phase 1, open-label trial of tanogitran in Thromboembolism (TE) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum measured concentration of the analyte in plasma at 48 hours, Time to reach the maximum concentration of the analyte in plasma at 48 hours and 22 more. Started Jun 2003; status: completed.
02
Drugs
tanogitran
03
Conditions
Thromboembolism (TE)
Beyond the preview
Go deeper on NCT02254070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254070.